Not actual patients with Fabry disease.
For adults with confirmed Fabry disease and an amenable GLA variant
Galafold is a small-molecule alpha-Gal A pharmacological chaperone that reversibly binds to the active site of alpha-Gal A and stabilizes the protein.1,2
Galafold restores the normal pathway for trafficking amenable alpha-Gal A to the lysosome.2
Galafold has a large apparent volume of distribution of approximately 89 L (range: 77 to 133 L) at steady state,2 suggesting it is well distributed into tissues.1,3
Galafold reduced disease substrate (GL-3) in kidney interstitial capillaries (KIC) over 6 months.2*
The most common adverse drug reactions reported with Galafold (≥10%) are headache, nasopharyngitis, urinary tract infection, nausea, and pyrexia.2
For adults with confirmed Fabry disease and an amenable GLA variant
Galafold is a small-molecule alpha-Gal A pharmacological chaperone that reversibly binds to the active site of alpha-Gal A and stabilizes the protein.1,2
Galafold restores the normal pathway for trafficking amenable alpha-Gal A to the lysosome.2
Galafold has a large apparent volume of distribution of approximately 89 L (range: 77 to 133 L) at steady state2, suggesting it is well distributed into tissues.1,3
Galafold reduced disease substrate (GL-3) in kidney interstitial capillaries (KIC) over 6 months.2*
The most common adverse drug reactions reported with Galafold (≥10%) are headache, nasopharyngitis, urinary tract infection, nausea, and pyrexia.2
*
Mean change in average number of GL-3 inclusions per KIC from Baseline to Month 6 was -0.04 (95% CI: -1.94, 0.26; n=25) with Galafold treatment vs -0.03 (95% CI: -1.00, 1.69; n=20) with placebo.2
†
Approximately 67% of patients who have taken Galafold since approval in August 2018 stayed on Galafold for at least 1 year.4
Please see Important Safety Information for Galafold below.
Watch this video to learn more about the mechanism of action for Galafold.
Watch this video to learn more about the mechanism of action for Galafold.
Starting with your patient's GLA genotype, you can determine whether the GLA variant is amenable in 1 of 3 ways:
The Galafold Full Prescribing Information includes a list of GLA variants that have been identified as amenable to Galafold.
GalafoldAmenabilityTable.com can be used to determine whether a specific GLA variant has been listed as amenable in the Full Prescribing Information.
For answers to questions about amenability, you can also contact Amicus Medical Information at
1-877-4-AMICUS or [email protected].
This form serves a dual purpose: as a prescription for Galafold and as a way for patients to register for AMICUS ASSIST®.
Help patients understand how to take Galafold with these helpful tips.